soul trial oral semaglutide cardiovascular outcomes 2025 results A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link Trial Scorecard: SOUL

your clinician reviews their current regulatory status with you before prescribing

Research published in Cell Reports Medicine in 2026 concluded directly: weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function

For example, reduced caloric intake due to appetite suppression may contribute to tiredness

However, these days, lots of people are using it in higher doses as a weight loss medication under the brand name Wegovy

Once-daily liraglutide and the once-weekly agents can be taken at any time of day, whereas twice-daily exenatide and once-daily lixisenatide must be taken within 1 hour before eating (713)